Sanofi shares slide as FDA delays Acomplia--again
Hit by some aggressive new generic competition and fresh from the loss last week of its patent for Lovenox, Sanofi-Aventis reported that the FDA has delayed a decision on its weight loss drug Acomplia for three months. That's the third delay for Acomplia and the wrong message from Sanofi-Aventis, which saw its share price slide on the news. Analysts say that Sanofi-Aventis badly needs to gain a blockbuster approval from regulators as Plavix and other big drugs face generic competition. The FDA now says it will decide on Acomplia by July, raising the possibility that the drug may also be OK'd for type 2 diabetes.
- read the report from MarketWatch
ALSO: The FDA has restricted the use of Ketek for pneumonia to address safety concerns. Release
Related Articles:
Delays forecasted for blockbuster obesity drug. Report
Sanofi shares slide on Acomplia delay. Report
Comments
Is there any more information available for Accomplia and Type 2 Diabetes?
Check out this link from our archives form more on Acomplia for diabetes:
http://www.fiercebiotech.com/story/sanofi-touts-phase-ii-acomplia-results/2006-12-05
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends

